Cold virus engineered to attack pancreatic cancer shows promise in early trial

NCT ID NCT02705196

Completed Disease control Sponsor: Lokon Pharma AB Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a modified cold virus called LOAd703 in 51 people with pancreatic cancer. The virus is designed to infect and kill cancer cells while also boosting the immune system. It was given alongside standard chemotherapy, and in some cases an immunotherapy drug, to see if it is safe and helps shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: delolimogene mupadenorepvec (LOAd703), an oncolytic virus that infects and kills cancer cells and stimulates the immune system
What this could lead to: If it works, this could point toward a new treatment option for pancreatic cancer by combining a virus that kills cancer cells with standard chemotherapy.
What could go wrong: This is an early-phase trial with only 51 participants, so results may not apply to all patients. The virus can cause fever and other immune reactions, and it is not yet approved by the FDA.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adenoviridae infectious disease malignant pancreatic neoplasm neoplasm pancreatic ductal adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC CANCER

Contacts and locations

Locations

Baylor College of Medicine

Houston, Texas, 77030, United States
Baylor St Luke's Medical Center

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.